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Abstract
This article examines the current status and most important changes over time to the legislative framework on the
health technology assessment-informed decision-making process on diagnostic and therapeutic ‘methods’ in
Germany. The relevant information was obtained through documentary analysis covering the period 1990 to 2017.
The findings show that, even if the outpatient care sector appears to be much more regulated than the inpatient
sector (based on a strict separation of the two care settings), developments in Germany have led to a more tightened
assessment framework, making the use of evidence a firm component in the decision-making process. Nevertheless, a
comprehensive approach for a systematic assessment of diagnostic and therapeutic ‘methods’ still does not exist.
Readjustments of current regulations in Germany, such as the existing ‘Verbotsvorbehalt’ (i.e. provision of a diagnostic
and therapeutic ‘method’ possible unless actively delisted) in the inpatient care setting, as well as further developments
at the European level are needed in order to create a system that ensures early access to innovation under controlled
study conditions.
Background
The debate on decision-making in healthcare informed
by evidence (health technology assessment; HTA) is not
a recent phenomenon. Many European countries have
introduced national or regional technology assessment
programmes during the past three decades [1–9], mainly
triggered by growing concerns over the benefit/value of
innovations in terms of outcomes relevant for patients,
safety and budget impact. The discussion about licensing
of medical devices (MDs) in Europe may serve as an ex-
ample. Complications with metal-on-metal hip implants
pointed towards systemic shortcomings of the current
regulation of MDs, which poses a clear threat to patient
safety. The widely held view that the system for MD
regulation in Europe is flawed, especially regarding the
regulatory requirements for clinical data on MDs,
triggered not only a stricter MD regulation at the
European Union (EU) level (e.g. the revision of the EU
directives) [10], but also stimulated activities at the
national level, as for example in Germany. This becomes
evident when considering legislative changes over past
years that comprise a more tightened decision-making
framework on hospital-based diagnostic and therapeutic
methods (‘Untersuchungs- und Behandlungsmethoden’;
more details regarding the definition are given in the
methods section) employing high-risk MDs, making the
use of HTA an essential aspect in the decision-making
process. However, besides the increased activity of HTA in
Europe and worldwide and the common remits, roles and
aims national healthcare systems share, there are differ-
ences in terms of its implementation and impact [1, 2].
For example, within the corporatist German system,
with its multitude of actors in the so-called self-
governance or self-administration, represented by the
Federal Joint Committee (Gemeinsamer Bundesausschuss,
G-BA), the process for HTA markedly differs to those in
most other countries [11]. In self-governance, payers and
providers are mandated to ensure access to and provision
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of health services [12]. This includes the assessment
process of diagnostic and therapeutic methods, on the one
hand, and the final decision by the same actors with
sometimes conflicting interests in these processes, on the
other. Moreover, different regulations for diagnostic and
therapeutic methods between the in- and outpatient care
setting in Germany exist. Whereas in outpatient care any
new diagnostic and therapeutic method must be evaluated
before being reimbursed (referred to as ‘Erlaubnisvorbe-
halt’ regulated under §135 of the Social Code Book Five;
SGB V), in inpatient care new diagnostic and therapeutic
methods are reimbursed without prior assessment, as long
as fundamental principles of quality and cost-effectiveness
are not violated and methods are not delisted by the G-
BA (referred to as ‘Verbotsvorbehalt’, regulated under
§137c SGB V).
Based on this and prompted by the current renewal of
long-standing debates about the permissiveness of the
German system compared to most other countries in terms
of coverage of innovative yet unproven technologies, this
study aims to examine the current status of evidence-based
assessment in the context of diagnostic and therapeutic
methods in Germany. Specifically, we focus on the role of
HTA in decisions on health service coverage. This includes
an analysis of the most important changes to the legislative
framework over time, the dynamics that have informed
them and their implications for the decision-maker.
Methods
This analysis is informed by documentary analysis from
1990 to 2017 on the important reforms and regulations,
focussing exclusively on evaluations/decisions of diag-
nostic and therapeutic methods.
The term ‘method’ has been evolving through several
legislative decisions over the past 20 years. It is currently
defined as a medical procedure as part of a physician-led
treatment concept and is characterised by a certain degree
of complexity, usually involving several steps, which may
include the use of MDs. Moreover, there has to be an
underlying theoretical and scientific concept, which differ-
entiates the method from others (e.g. pharmaceuticals or
one-step procedures) and thus justifies its systematic
application in the diagnosis and treatment of specific
diseases [13]. Consequently, this understanding of a pro-
cedure encompasses a broad spectrum of new diagnostic
and therapeutic methods and entails a broader conception
than the application of MDs alone [14].
Documents included were legal texts (e.g. records of
court decisions), final scientific reports of coverage
decisions after benefit assessments (including related
justifications/reasons) by the Institute for Quality and
Efficiency in Health Care (Institut für Qualität und
Wirtschaftlichkeit im Gesundheitswesen; IQWiG) or
other research institutes commissioned to conduct
evidence reviews, selected publications on diagnostic
and therapeutic methods, and materials from (govern-
mental) websites or digital databases and/or archives
(e.g. juris database; G-BA’s document management
system) such as policy documents relating to the assess-
ment of diagnostic and therapeutic methods published
by the G-BA and by corporatist organisations.
HTA in the German decision-making process for
diagnostic and therapeutic methods – early
development and the actors involved
HTA is defined as “any process of examining and report-
ing properties of a medical technology used in healthcare,
such as safety, efficacy, feasibility, and indications for
use, cost, and cost-effectiveness, as well as social,
economic, and ethical consequences, whether intended or
unintended” [15]. In Germany, HTA has been under dis-
cussion since the mid-1990s, closely related to the rise
of evidence-based medicine (EbM). The principles and
methods of HTA were continuously adopted by various
decision-making bodies in Germany, such as the Federal
Standing Committee of Physicians and Sickness Funds,
the Hospital Committee and the coordination committee
[16]. In 2004, within the Statutory Health Insurance
(SHI) Modernisation Act, these committees were trans-
formed into the G-BA. The basis for the work of the G-
BA is the German SGB V, which defines the health
policy framework in which the G-BA operates. This legis-
lative framework is set by both chambers of parliament.
The G-BA is the highest decision-making body of the joint
self-government of physicians, dentists, hospitals and
health insurance funds in Germany. Associations of
office-based physicians (Kassenärztliche Bundesvereini-
gung (Federal Association of SHI Physicians)), dentists
(Kassenzahnärztliche Bundesvereinigung (Federal Associ-
ation of SHI Dentists)), hospitals (Deutsche Krankenhaus-
gesellschaft (German Hospital Federation)), sickness funds
(GKV-Spitzenverband (Federal Association of Sickness
Funds)) and patients’ representatives are embodied in the
G-BA’s decision-making committees [12]. The G-BA is-
sues directives and thus determines the details of the
statutory regulations. To inform the G-BA’s coverage
decisions by an independent evidence assessment, the
legislator in parallel also created the IQWiG. Its main task
is to produce HTA reports on, for example, pharmaceuti-
cals or diagnostic and therapeutic methods [17, 18]. While
the establishment of IQWiG illustrates the separation of
addressing the evidence within a standardised process of
providing an HTA report to the G-BA, and the (coverage)
decision-making process within the G-BA, in practice
there is interaction between these processes. The G-BA
does not necessarily follow the recommendations issued
by IQWiG or requests additional evidence either from
IQWiG or from other sources.
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A harmonisation of the basic rules set by the legislator
of the two sectors (Verbotsvorbehalt and Erlaubnisvorbe-
halt) was not established, so the same evidence can lead
to different decisions. In addition, the G-BA was not
authorised to initiate studies in situations where the
evidence body was thought to be insufficient. To under-
stand the current situation in Germany, it is therefore
important to be familiar with further regulations set
from 2012 onwards.
The following two sections describe the processes
prior to 2012 and from 2012 onwards in detail. As
already indicated above, different regulations for the
assessment of diagnostic and therapeutic methods be-
tween the in- and outpatient setting in Germany exist.
Therefore, the two sectors need to be addressed separately
with respect to their impact on assessment approaches
within the context of evidence-based decision-making.
Assessment approaches of diagnostic and
therapeutic methods prior to 2012
The use of scientific evidence plays one key role in the
decisions of the G-BA. This becomes clear by the fact
that it is embedded in the G-BAs’ rules of procedure
(Verfahrensordnung), which are founded on the inter-
national principles of EbM. Applying these principles
means integrating the best available scientific evidence
with clinical expertise and patient values [19]. Moreover,
the rules of procedure make specific stipulations for
decision on the coverage of new diagnostic and thera-
peutic methods, stating that they have to demonstrate
evidence of the “accepted state of medical knowledge
about the benefits, necessity and efficiency”; methods that
are “not necessary or inefficient” should not be included
in the SHI benefit basket [20]. However, as to what con-
stitutes necessity is sometimes controversial between the
actors in the G-BA.
Assessment approaches of diagnostic and therapeutic
methods in the outpatient sector
Period from 1990 to 1997
In the 1990s, the Federal Standing Committee of Physi-
cians and Sickness Funds (the predecessor of the G-BA)
established the evidence-based assessment of diagnostic
and therapeutic methods in the outpatient care setting
[21]. This was triggered by rising criticism that decisions
were intransparent and essentially based on statements
by purely relying on the opinion of individual experts
rather than relying on critical appraisal of scientific evi-
dence available. Concerns had been raised regarding the
implementation of a more transparent and reliable
evidence-based assessment approach. As a reaction, the
Federal Standing Committee of Physicians and Sickness
Funds incorporated the evidence-based selection and
assessment of the scientific literature as a basis for
decisions regarding the inclusion or exclusion of diag-
nostic and therapeutic methods in the SHI benefit bas-
ket. Furthermore, resulting from the transition to the
so-called NUB-directives, which is the acronym for
‘Neue Untersuchungs- und Behandlungsmethoden’, the
classification of scientific studies with different trial de-
signs (and varying certainty of the results) became a
legal component for the assessment process [21, 22]
(Fig. 1). The ambulatory execution of low-density lipo-
protein elimination as an extracorporeal apheresis was
the first accepted diagnostic and therapeutic method
under these newly introduced NUB-directives. For seven
methods, such as the Heidelberg capsule, electro acu-
puncture according to Voll or the immune-augmentative
therapy, no therapeutic and/or diagnostic benefit was
approved by the committee. Therefore, these methods
were not included in the SHI benefit basket [23].
Period from 1998 to 2011
Despite these developments until 1997, the decision-
making process of the Federal Standing Committee of
Physicians and Sickness Funds was less transparent, as
only the decisions themselves were published but not
how they were formed (i.e. through published rules of
procedure). Its work was being increasingly denounced
as arbitrary and incoherent [24]. In the context of this
criticism, the Federal Association of SHI Physicians, to-
gether with representatives of the sickness funds, devel-
oped a new mode of operation as of January 1, 1998.
This led to the implementation of a procedural guideline
for evidence-based assessment in the subcommittee on
medical treatment (within the second SHI Restructuring
Act in 1997), which introduced further substantial
changes of the regulatory framework, especially improv-
ing the transparency of the decision-making process.
Specifically, this included, for example, (1) publication of
the process for assessment, (2) publication of the con-
sultancy topic with a general call for written comments
and (3) publication of a comprehensive final report
including a presentation of the comments, the scientific
literature, the entire consultation process and the con-
sultancy results [17, 21, 25]. In addition, this reform
extended the Committee’s assessment responsibilities to
the assessment of already established methods (Fig. 1).
In November 1997, the Federal Standing Committee of
Physicians and Sickness Funds published its first an-
nouncement listing two established technologies for re-
assessment, i.e. bone densitometry measurement and
methadone substitution, and six new technologies for
evaluation. A second announcement in June 1998 listed
an additional seven new technologies for assessment
[22]. The final decision regarding the bone densitometry
measurement in 1999 represents an important example
for informed decision-making using HTA. In addition to
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written statements, guidelines, and an analysis of the sci-
entific literature, a HTA report [26], commissioned by
the Federal Ministry of Health, was considered during
the decision-making process. Based on all findings, bone
densitometry measurement was the first method issued
with a restriction to a specific indication due to a lack of
evidence for the remaining indications.
Prior to 2012, it was possible to suspend benefit as-
sessments for methods, if valid studies were expected to
be finalised and/or published in the near future. How-
ever, there was no possibility to commission evaluation,
such as the initiation of a clinical trial, if study evidence
was missing (Table 1). This was only possible as pilot
projects within separate contracts between sickness
Table 1 Assessment approaches of the G-BA and resulting consequences for provision prior to and after 2012
Outpatient Inpatient
Until 2011 Since 2012 a),b) 2000-2011 2012-2016 a),b) Since 2017
Before evaluation Not in benefit basket,
i.e. provision not
reimbursable
Not in benefit basket,
i.e. provision not
reimbursable
Provision allowed Provision allowed Provision allowed,
unless method under
§ 137h
After evaluation
Proven benefit Acknowledg-ment and
inclusion in benefit
basket
Acknowledg-ment and
inclusion in benefit
basket
Continued
provision
Continued
provision
Continued provision/
inclusion in benefit
basket (§ 137h)
No proven benefit + no ‘potential’ No acknowledge-ment,
i.e. non-inclusion into
benefit basket
No acknowledge-ment,
i.e. non-inclusion into
benefit basket
Exclusion from
benefit basket
Exclusion from
benefit basket
Exclusion/ non-
inclusion (§ 137h)
No proven benefit, but clinical
studies expected (= ‘potential’)
Suspension of the
decision until studies
available
Suspension of the
decision until studies
available
Suspension of the
decision until
studies available
Suspension of the
decision until
studies available
Trial implementation
(under § 137e)
Insufficient evidence, indication of
possible benefit, no clinical studies
expected/ planned (= ‘potential’)
Approach not existent Trial implementation
(under § 137e)
Approach not
existent
Trial
implementation
(under § 137e)
Trial implementation
(under § 137e)
a) The new regulations since 2012 complement the existing directives in the in- and outpatient care setting (§§ 135 and 137c SGB V)
b) The term ’potential’ was introduced in 2012 in conjunction with the regulation under § 137e SGB V. This new assessment category requires a method to show potential
being a valid diagnostic or treatment alternative to warrant the implementation of a trial. Additionally, the presence of a ’potential’ inhibits the exclusion of a method
Fig. 1 Regulatory milestones regarding the assessment of diagnostic and therapeutic methods in Germany (simplified illustration)
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funds and physicians. One example is the decision on
acupuncture. In this case, the G-BA concluded that
evidence for efficacy, safety and effectiveness was not
sufficient to decide on SHI coverage, but that a compre-
hensive assessment of these factors in relation to chronic
low back pain, chronic headache and chronic painful
arthritis of large joints was required. Consequently,
many sickness funds consecutively launched three major
acupuncture pilot projects, including randomised con-
trolled trials, to assess these three indications.
Assessment approaches of diagnostic and therapeutic
methods in the inpatient sector
Most new diagnostic and therapeutic methods in
Germany are first introduced in the inpatient sector,
which is based on the principle referred to as Verbots-
vorbehalt (regulated under §137c SGB V). This means
that the provision of all diagnostic and therapeutic
methods, including new ones, is allowed without any as-
sessment of their benefit. In consequence, the G-BA has
to decide only on the restriction or exclusion of already
applied methods [14]. The primary intention by the
legislator of this rule is to ensure that insured patients
are rapidly able to take advantage of innovative methods
of treatment. Therefore, in the inpatient sector, innova-
tions in diagnostic and therapeutic methods find
conditions that enable their rapid application in clinical
practice [27]. However, the Verbotsvorbehalt also creates
fundamental disincentives, as it releases manufacturers
and hospitals from the responsibility to carry out valid
studies needed to assess benefit and safety [28].
Period prior to 2012
Prior to 2000, the introduction of diagnostic and thera-
peutic methods was managed by individual hospitals in
the context of budget negotiations with sickness funds or
of applications for capital investment from the states [29].
In 2000, the SHI Reform Act was introduced. Based
on this new legislation, a committee was established to
assess whether a method sufficiently complies with the
quality requirements defined by the SGB V [30]. Assess-
ments have to be made in accordance with the processes
established in the outpatient care setting, making the ap-
plication of the principles of EbM also mandatory in the
inpatient care sector (Fig. 1). The first indications
announced for assessment under this new reform were
autologous chondrocyte implantation, hyperbaric oxygen
therapy and proton beam therapy [31]. However, under
§137c SGB V, assessments in the inpatient setting can
only be initiated by the request of representative
stakeholders in cases where, for example, an indication
of a negative risk-benefit ratio of a method exists. Con-
sequently, in most cases, a benefit assessment occurs at
a point in time when methods have already been
established in the healthcare system for many years,
despite considerable doubts as to whether their applica-
tion sufficiently meets the quality requirements [28].
This means that, by the end of 2011, the G-BA was only
able to exclude methods in few cases if their benefit was
not proven. Still, a systematic assessment of the
methods’ benefit (or harm) was not a fixed component
under the regulation based on §137c SGB V (Table 1).
Assessment approaches of diagnostic and
therapeutic methods from 2012 onwards
The developments described in the previous sections, es-
pecially the formation of the G-BA and IQWiG in 2004,
reflect that the use of scientific evidence has become
more relevant in decision-making over time. However,
as in prior to 2012, still only a fraction of all innovations
have been assessed since 2012, and differently in the in-
and outpatient care sector. This can be explained by
remaining inconsistencies between the two healthcare
sectors in Germany [32]. Such inconsistencies constitute
barriers for a successful implementation of assessment
approaches within the scope of coverage decisions.
Additional regulations outlined in the following sections
have been, and are still being, introduced aiming at elim-
inating these inconsistencies.
Introduction of the coverage with evidence development
(CED) reform (§137e SGB V)
Health policy makers have partially responded to the
criticism from, for example, scientific associations, re-
searchers and expert networks of the Verbotsvorbehalt
in the inpatient care setting by introducing (within the
SHI Care Structures Act in 2012) the testing regulation
(Fig. 1), which can be considered a variety of the CED
reform [14, 33]. This newly introduced stipulation (regu-
lated under §137e SGB V) complements the existing
regulations in the in- and outpatient care setting (§135
and §137c SGB V) (Fig. 2).
Consequently, the G-BA is not only able to assess the
evidence, but also to initiate high-quality clinical studies.
A key element when assessing a new method under the
testing regulation is the determination of the ‘potential’
(i.e. promise of benefit) for being a valid diagnostic or
treatment alternative, which is carried out by the IQWiG
[34]. The potential is assessed against the mechanism of
action of the new technology and the evidence available.
Particularly, the method should likely be more effective,
less complicated, less invasive, less harmful, or able to
replace less efficacious methods in specific groups of
patients [14]. This determination precedes each decision
on testing according to §137e SGB V, which requires the
presence of sufficient potential to warrant the generation
of scientific evidence for a subsequent benefit assess-
ment in a new study [27].
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In cases where the G-BA – on the basis of the
IQWiG’s results – assesses the method as showing
potential and decides to conduct a trial, it develops
and publishes a so called ‘testing directive’, which
defines a trial phase for the method in question and
commissions an independent scientific institute to
plan and conduct the evaluation (Table 1) [14, 27].
Nevertheless, only few decisions have been published
since the introduction of the testing regulation and
no trial in the context of the testing directive has
been conducted yet (reasons include difficulties re-
garding financing, the complex application process or
the voluntary nature of this tool) (Table 2). Moreover,
criticisms regarding the lack of transparency (e.g. lack
of public information regarding new applications, no
publication of negative G-BA votes on methods) as
well as the long duration of the decision process
remain. These aspects are of importance with respect
to patient safety as, even if the implementation of a
testing directive is initiated, the method in question
remains available in the inpatient care setting (i.e.
under §137c SGB V) without definitive knowledge
about its benefit or harm for the patient.
Based on the same law, the legislator amended the vot-
ing rules in the G-BA and consequently increased the
hurdle for the exclusion of a method. This is evident
firstly in the introduced requirement of the two-thirds
majority for such a decision, whereas a simple majority
in the decision-making body still suffices for inclusion of
a new method. Secondly, the increase in the hurdle is
shown even more clearly by an amendment of §137c
SGB V, which states that:
(1)a method can only be excluded directly if the G-BA
explicitly ascertains the ineffectiveness or even harm
of the method, and
(2)if the benefit of a method has not yet been adequately
proven, but offers the potential of being a treatment
alternative, the G-BA decides to issue a testing
directive under §137e SGB V (Fig. 1) [20].
Accordingly, as stated by the former impartial chair-
man of the G-BA, Rainer Hess, methods can no longer
be excluded directly, but only if they fall under the
testing directive, are consequently evaluated, and show no
potential to benefit or cause harm [35]. This requirement
Fig. 2 Assessment pathway of diagnostic and therapeutic methods in Germany (simplified)
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represents a reversal of the burden of proof and thus con-
stitutes a retrograde step. It stands in clear contrast to the
regulations concerning pharmaceuticals, for which a proof
of the efficacy and safety has to be provided a priori within
the framework of the market authorisation process [27].
Thus, the quality requirements defined by the SGB V in
the inpatient care setting apply only to a limited extent, as
‘potential’ does not automatically mean that the method
has any (proven) benefit or is free of harm. This involves
the risk that, the longer innovations are being used outside
the actually required studies, i.e. the more they become
established in routine care, generation of valid clinical data
on effectiveness and/or safety becomes less likely. More-
over, examples in the past (e.g. the metal-on-metal hip
implant scandal and experiences like stents for the treat-
ment of intracranial stenosis) have shown that innovations
often can be ineffective or even harmful. In order to
protect patients from such potentially harmful interven-
tions, the German legislature aimed at correcting the
deficiencies of the existing regulations by introducing a
mandatory benefit assessment of diagnostic and thera-
peutic methods based on high-risk MDs [27, 32, 36]. The
details of this new regulation will be outlined in the
following section.
The early benefit assessment reform (§137h SGB V)
A new stipulation, based on the SHI Care Provision
Strengthening Act in 2015, has been recently set in place
(Fig. 1). This new directive (referred to as §137h SGB V)
amends the existing regulations under §137c and §137e
SGB V (Fig. 2) and further extends the possibilities of
the G-BA with respect to the assessment of new diag-
nostic and therapeutic methods in the inpatient care
setting. More precisely, this new directive commissions
the G-BA to perform an early benefit assessment regard-
ing new diagnostic and therapeutic methods based on
high-risk MDs. According to the legal provisions, new
diagnostic and therapeutic methods that are based on a
‘new theoretical and scientific concept’ and involve the
use of highly-invasive class IIb, III or active implantable
MDs are subject to the new assessment regulation.
Originally, the Government Coalition Agreement of
2013 stated that “hospitals that use new high-risk
medical products will be obliged to participate in benefit
and safety studies of the G-BA during the post-market
launch phase” [36]. These would be, according to the
valid definition of MDs, all devices of risk classes IIb
and III. However, after passing through Parliament and
the Federal Ministry of Health, only ‘highly invasive’
MDs meeting the criteria mentioned above remained
subject to the new assessment regulation [28, 36]. Con-
sequently, only a fraction of what was actually
envisioned in the coalition agreement will be subject to
the early benefit assessment by the G-BA [37]. Specific-
ally, as published by the G-BA on March 17, 2017 [38],
the number of eligible diagnostic and therapeutic
methods currently amounts to only eight.
Discussion
Much research has been undertaken to date describing
and comparing HTA activities across organisations and
countries, documenting a general increase in HTA
utilisation in Europe and worldwide [1, 2, 39–42]. More-
over, these studies also show a considerable variety in
HTA processes as well as the methods for evaluation
that are dependent on, for example, the nature of the
Table 2 Methods fulfilling the criteria of the testing regulation (§137e SGB V) [49]
Year Introduction of diagnostic and therapeutic methods according to the testing regulation (§137e SGB V)
2014 Non-invasive prenatal diagnosis to determine the risk of fetal trisomy 21 by means of molecular genetic testing
Hyperbaric oxygen therapy during sudden hearing loss
Measurement of fractionated exhaled nitric oxide for the detection of eosinophilic airway inflammation
Measurement of fractionated exhaled monoxide for the control of asthma treatment during
pregnancy
2015 Electric stimulation for tissue defect treatment in venous leg ulcers
Electric stimulation for tissue defect treatment in diabetic foot ulcers
Transcorneal electric stimulation in retinopathy pigmentosa
Magnetic resonance tomography-controlled highly-focused ultrasound therapy for the treatment of the
uterine myoma
2016 PET/CT in malignant lymphomas
Measurement and monitoring of the pulmonary arterial pressure by an implanted sensor for the
therapy optimisation in cardiac insufficiency in stage NYHA III
2017 Ultrasound-guided high-intensity-focused ultrasound for the treatment of uterine leiomyomas
Ultrasound-guided high-intensity-focused ultrasound for the treatment of non-surgically treatable
hepatocellular carcinoma
CT computed tomography, PET positron emission tomography, NYHA New York Heart Association, SGB V Fifth Social Code Book
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issue, the types, quality and quantity of the available
studies, and the degree to which the issue affects stake-
holders’ interests [43]. This variety reflects the diversity
of healthcare and policy systems with their different
mandates, coverage-decision mechanisms and roles of
key actors in the decision-making process [44]. Within
this context, Germany, with its unique self-administration
system, can serve as a valuable example regarding cover-
age decisions on health services. The complexity of this
self-administration system, with its multitude of actors in
the decision-making process (i.e. corporatist system),
becomes even more intense due to the different existing
pathways regarding the regulatory mechanisms for
diagnostic and therapeutic methods. Therefore, this study
aimed at exploring the current status of the decision-
making process regarding diagnostic and therapeutic
methods in Germany. We specifically analysed the most
important changes to the legislative framework over the
last 20 years, focussing on the role of scientific evidence
(HTA) in informing those decisions.
Our analysis shows that HTA-informed decision-
making on diagnostic and therapeutic methods in
Germany was not a major issue until 1997. However,
from 1998 onward, and in particular after 2012, the im-
portance of evidence utilisation (HTA) in legitimising
decisions, despite some conflicting steps (e.g. the two-
third majority for the exclusion of a method), increased
overall. These developments took place regardless of the
respective government and were especially geared towards
the inpatient care setting, while the outpatient care setting
appeared to be much more regulated right from the
beginning of technology assessment. Prior to the German
self-administration, the uptake of HTA-informed decision-
making was met with hope from the payer’s side for more
control of (promising, yet expensive) unproven innovations,
but provoked resistance from hospital organisations who
were afraid of not previously existent restrictions in service
provision. In addition, since in- and outpatient carers
are also competitors for many treatment options,
HTA-informed decision-making interferes with con-
flicting interests of decision-makers in several ways.
Shaping the framework for HTA-informed decision-making
on diagnostic and therapeutic methods prior to 2012
The introduction of a procedural guideline for an
evidence-based assessment of new diagnostic and thera-
peutic methods by the Federal Standing Committee of
Physicians and Sickness Funds in 1998 can be inter-
preted as the first milestone in which scientific evidence
use has become institutionally embedded in the decision
process of health policy in Germany. In 1997, the tasks
of the G-BA were extended from the exclusive assess-
ment of new methods to an assessment of already estab-
lished ones in the outpatient care setting. This
foresighted decision and a number of further key legisla-
tive changes, including the introduction of a coordinat-
ing committee for technology assessment in the
ambulatory and hospital sector and the establishment of
HTA programmes, especially the IQWiG in 2004, con-
tinuously extended and increasingly converted the evalu-
ation of diagnostic and therapeutic methods into an
evidence-based assessment process until the end of
2011. However, despite the relevance of HTA having in-
creased, our analysis shows that, since then, its impact
could have been higher. Specifically, until the end of
2011, the G-BA could only exclude (or suspend)
methods in case of proven harm or lacking evidence re-
garding patient benefit, but had no tools to commission
evaluations in the case of missing evidence [18].
Further advancements regarding HTA-informed decision-
making on diagnostic and therapeutic methods from
2012 onwards
To address the above mentioned shortcoming, the CED
(regulated under §137e SGB V) model established in
2012 further expanded the legal framework of the G-BA
regarding the generation of evidence. However, even if
under this approach a study for the assessment of the
method in question is initiated, the method can still be
provided in the inpatient care setting until a decision
based on the completed trial has been taken. Moreover,
subsequent regulations, such as the introduction of the
two-third majority for the exclusion of a method as well
as the establishment of the concept of a ‘potential’, con-
siderably increased the hurdles for an exclusion of a
method [45, 46]. This is alarming, as patients might be
exposed to a potentially harmful method. To avoid repe-
tition of problems such as those experienced with intra-
cranial stents, the German Parliament recently decided
on an extension in the law introducing a new rule
(§137h SGB V) in which new diagnostic and therapeutic
methods based on a high-risk MD must undergo a
formal HTA process prior to being covered by the
healthcare system [36, 37]. Based on this, the controver-
sial principle of the Verbotsvorbehalt (in accordance with
§137c SGB V) in hospitals was partly replaced by these
processes. Aside from the recent developments at the
European level regarding the stricter regulation of MDs,
the current legislative change in Germany, namely
setting a HTA of high-risk diagnostic and therapeutic
methods, may ensure the necessary degree of safety of a
treatment in the future at the national level.
The G-BAs future role among other European assessment
bodies
The institutionalisation of HTA in different European
countries began in the late 1980s. Sweden established
one of the first HTA agencies in 1987. Various national
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HTA programmes followed and further shaped the con-
cept of HTA in the 1990s [47]. Among these pro-
grammes, the United Kingdom’s National Institute for
Health and Care Excellence (NICE) is one of Europe’s
largest and longest established assessment bodies. It
might be possible that the United Kingdom’s decision to
leave the EU will have consequences for NICE’s future
contributions to the European regulatory and HTA net-
works such as EUnetHTA (e.g. assessments, partially or
completely independent and different from the European
consensus). Although the details will have to be deter-
mined over the coming years, other regulators and HTA
bodies in the EU, such as the G-BA (strong regulator)
and the IQWiG (methodological leadership), might as-
sume more responsibility in a post-Brexit EU, especially
considering that the German market for MDs is the
largest in Europe [48].
Strengths and limitations
The strength of this work lies in its extensive documen-
tary analysis between 1990 and 2017. To our knowledge,
this is the first study to examine the current status and
most important legislative changes over time regarding
the HTA-informed decision-making process of diagnos-
tic and therapeutic methods in Germany. However, we
acknowledge some limitations. Firstly, documentary
analysis is a useful research tool with considerable merit
as a methodology for policy evaluation and reform.
However, future research might extend this analysis by
other methodological approaches (e.g. validation by an
interview survey). Secondly, focus on the decision-
making process of diagnostic and therapeutic methods
does not allow any conclusions for other health policy
areas such as the regulation of pharmaceuticals.
Conclusion
This analysis shows that, over the last 20 years, health-
care politics in Germany have been characterised by a
large number of reforms that led to the development
and application of new procedures. This led to a
continuous extension of the regulatory assessment ap-
proaches of the G-BA, making evidence-based assess-
ment an indispensable feature of the SHI system.
However, even with the most recently introduced benefit
assessment for certain diagnostic and therapeutic
methods, including high-risk MDs, the legislator failed
to create a comprehensive approach for a systematic
assessment of diagnostic and therapeutic methods in
Germany. Therefore, these developments should be
interpreted as a ‘learning system’, in which certain
issues still remain to be resolved (e.g. discrepant ap-
proaches to coverage decisions between ambulatory
and hospital care).
To overcome the uncertainty regarding the effective-
ness and safety of a method, particularly in the inpatient
sector, a regulatory framework is needed to protect
patients from ineffective or even harmful methods. This
implies mandatory assessments of new methods con-
ducted within acceptable deadlines in order to realise
both a fast access to diagnostic and therapeutic methods
for patients and planning security for manufacturers.
The realisation of this approach does imply a realign-
ment of the current regulations in Germany as well as
further actions at the European level, helping to contain
the risks associated with access to technologies without
a robust evidence base.
Abbreviations
CED: coverage with evidence development; G-BA: Gemeinsamer Bundesausschuss
(Federal Joint Committee); EBM: evidence-based medicine; EU: European
Union; HTA: health technology assessment; IQWiG: Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and
Efficiency in Health Care); MD: medical device; NUB: Neue Untersuchungs- und
Behandlungsmethoden (new diagnostic and therapeutic methods); NYHA: New
York Heart Association; SGB V: Fünftes Sozialgesetzbuch (Fifth Social Code
Book); SHI: statutory health insurance.
Acknowledgements
We are grateful for the reviewers' constructive input.
Funding
The authors declare that there was no source of funding.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
BO developed the research question, performed the analyses, interpreted the
results and prepared the initial manuscript. SF, KM, AN, MP and RB interpreted
the results and critically reviewed the manuscript. All authors read and
approved the final manuscript.
Authors' information
BO, KM, AN and MP work for the Federal Joint Committee (G-BA), which is
the highest decision-making body of the joint self-government of physicians,
dentists, hospitals and health insurance funds in Germany. One of its tasks is
issuing directives determining the benefit basket of the statutory health
insurance funds (GKV). BO is also a PhD candidate and MP a guest lecturer
at Berlin University of Technology.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Olberg et al. Health Research Policy and Systems  (2017) 15:89 Page 9 of 11
Received: 24 May 2017 Accepted: 20 September 2017
References
1. Fuchs S, Olberg B, Panteli D, Perleth M, Busse R. HTA of medical devices:
Challenges and ideas for the future from a European perspective. Health
Policy. 2017;121(3):215–29.
2. Ciani O, Wilcher B, Blankart CR, Hatz M, Rupel VP, Erker RS, et al. Health
technology assessment of medical devices: a survey of non-European Union
agencies. Int J Technol Assess Health Care. 2015;31(3):154–65.
3. Banta D, Kristensen F, Jonsson E. A history of health technology assessment
at the European level. Int J Technol Assess Health Care. 2009;25(S1):68–73.
4. Cleemput I, Van Wilder P. History of health technology assessment in
Belgium. Int J Technol Assess Health Care. 2009;25(S1):82–7.
5. Hailey D. The history of health technology assessment in Australia. Int J
Technol Assess Health Care. 2009;25(S1):61–7.
6. Jonsson E. History of health technology assessment in Sweden. Int J
Technol Assess Health Care. 2009;25(S1):42–52.
7. Wild C. Austria: history of health technology assessment during the past 20
years. Int J Technol Assess Health Care. 2009;25(S1):74–81.
8. Perleth M, Gibis B, Göhlen B. A short history of health technology
assessment in Germany. Int J Technol Assess Health Care. 2009;25(1):112–9.
9. Weill C, Banta D. Development of health technology assessment in France.
Int J Technol Assess Health Care. 2009;25(S1):108–11.
10. European Commission. Revisions of Medical Device Directives. 2017.
http://ec.europa.eu/growth/sectors/medical-devices/regulatory-framework/
revision/index_en.htm. Accessed 1 Aug 2017.
11. Ettelt S. The politics of evidence use in health policy making in Germany –
the case of regulating hospital minimum volumes. J Health Polit Policy Law.
2017;42(3):513–38.
12. Busse R, Blümel M, Knieps F, Bärnighausen T. Statutory health insurance in
Germany: a health system shaped by 135 years of solidarity, self-
governance, and competition. Lancet. 2017;390(10097):882–97.
13. Bundessozialgericht (Federal Social Court). Urteil vom 17 Februar 2010. Az. B 1
KR 10/09 R. 2010. https://openjur.de/u/169605.print. Accessed 28 Apr 2017.
14. Olberg B, Perleth M, Busse R. The new regulation to investigate potentially
beneficial diagnostic and therapeutic methods in Germany: up to
international standard? Health Policy. 2014;117(2):135–45.
15. Institute of Medicine. Assessing Medical Technologies. Washington, DC:
National Academy Press; 1985.
16. Fricke FU, Dauben HP. Health technology assessment: a perspective from
Germany. Value Health. 2009;12 Suppl 2:20–7.
17. Busse R. Bedeutung von Health Technology Assessment bei Bewertungs-
und Erstattungsentscheidungen in Deutschland heute und morgen.
Gesundh ökon Qual manag. 2005;10:52–8.
18. Kreis J, Busse R. From evidence assessments to coverage decisions? The
case example of glinides in Germany. Health Policy. 2012;104(1):27–31.
19. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence
based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71–2.
20. SGB V; Das Fünfte Buch Sozialgesetzbuch - Gesetzliche Krankenversicherung
[SGB V Social Code Book: Statutory Health Insurance] (Artikel 1 des Gesetzes
vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das durch Artikel 1 des
Gesetzes vom 4. April 2017 (BGBl. I S. 778) geändert worden ist.
https://www.gesetze-im-internet.de/sgb_5/SGB_5.pdf. Accessed 5 Oct 2017.
21. Bertelsmann H, Roters D, Bronner D. Vom Nutzen der Nutzenbewertung:
Die Prinzipien der evidenzbasierten Medizin und des Health Technology
assessments als Entscheidungsgrundlage des Gemeinsamen
Bundesausschusses. Z Ärztl Fortbild Qualitätssich. 2007;101(7):455–62.
22. Bundesausschuss der Ärzte und Krankenkassen (Federal Standing
Committee of Physicians and Sickness Funds). Richtlinien des
Bundesausschusses der Ärzte und Krankenkassen über die Einführung neuer
Untersuchungs- und Behandlungsmethoden und über die Überprüfung
erbrachter vertragsärztlicher Leistungen gemäß §135 Abs.1 in Verbindung
mit §92 Abs. 1 Satz 2 Nr. 5 Fünftes Buch Sozialgesetzbuch (SGB V). 1997.
https://www.g-ba.de/downloads/62-492-193/RL_NUB-1997-10-01.pdf.
Accessed 15 May 2017.
23. Bundesausschuss der Ärzte und Krankenkassen (Federal Standing
Committee of Physicians and Sickness Funds). NUB-Richtlinien.
Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über
die Einführung neuer Untersuchungs- und Behandlungsmethoden. 1990.
https://www.g-ba.de/downloads/62-492-192/RL_NUB-1990-12-04.pdf.
Accessed 26 Apr 2017.
24. Blum K, Offermanns M. Anspruch und Realität von Budgetverhandlungen
zur Umsetzung medizintechnischer Innovationen. Gutachten des Deutschen
Krankenhausinstituts (DKI) im Auftrag des Bundesverbandes
Medizintechnologie (BVMed). Düsseldorf: Deutsches Krankenhausinstitut.
2009. https://www.dki.de/sites/default/files/publikationen/gutachten_
innovationstransfer_nub.pdf. Accessed 5 Oct 2017.
25. Deutsches Ärzteblatt. Zur Verfahrensordnung des Gemeinsamen
Bundesausschusses (G-BA). 2005. https://www.aerzteblatt.de/pdf/102/42/
a2890.pdf. Accessed 17 Apr 2017.
26 Lühmann D, Kohlmann T, Raspe H. Use of bone densitometry in the
framework of prevention and therapy of osteoporosis. Example of a
systematic evaluation (health technology assessment). Z Arztl Fortbild
Qualitatssich. 2000;94(6):475–81.
27 SVR (Sachverständigenrat). Sachverständigenrat zur Begutachtung der
Entwicklung im Gesundheitswesen. Bedarfsgerechte Versorgung –
Perspektiven für ländliche Regionen und ausgewählte Leistungsbereiche.
2014. http://www.svr-gesundheit.de/fileadmin/user_upload/Gutachten/
2014/SVR-Gutachten_2014_Langfassung.pdf. Accessed 5 Oct 2017.
28 Dettloff M, Wolf K, Egger B. Innovationen zum Nutzen der Patientinnen und
Patienten. 2016. https://www.gkv-90prozent.de/ausgabe/03/autorenbeitrag/
03_innovationen-medizinprodukte/03_innovationen-medizinprodukte.html.
Accessed 5 Oct 2017.
29 Busse R, Riesberg A. Health care systems in transition: Germany.
Copenhagen: European Observatory on Health Systems and Policies; 2004.
30 Deutscher Bundestag (German Bundestag). Gesetzentwurf der Fraktionen
SPD und BÜNDNIS 90/DIE GRÜNEN: Entwurf eines Gesetzes zur Reform der
gesetzlichen Krankenversicherung ab dem Jahr 2000 (GKV-
Gesundheitsreform 2000). 1999. http://dipbt.bundestag.de/doc/btd/14/012/
1401245.pdf. Accessed 5 May 2017.
31 Bundesanzeiger. Bekanntmachung der aktuellen Beratungsthemen des
Ausschusses Krankenhaus gemäß §137c Fünftes Buch Sozialgesetzbuch
(SGB V). 2002. https://www.g-ba.de/downloads/39-261-1019/2002-05-30-
khb-beratung-aci.pdf. Accessed 26 Apr 2017.
32 Perleth M. Nutzenbewertung und „frühe Nutzenbewertung“ nicht-
medikamentöser Verfahren – Gemeinsamkeiten und Unterschiede -
Methoden und Einfluss von Stellungnahmen. Presentation at the AWMF
workshop. 2016. http://www.awmf.org/fileadmin/user_upload/Die_AWMF/
Veranstaltungen/AWMF_im_Dialog/AiD_Stellungnahmen_2016/2016-07_
AiD_Perleth.pdf. Accessed 5 Oct 2017.
33 Bundesgesetzblatt. Gesetz zur Verbesserung der Versorgungsstrukturen in
der gesetzlichen Krankenversicherung (GKV-Versorgungsstrukturgesetz –
GKV-VStG). Teil I Nr. 70, ausgegeben zu Bonn am 28 Dezember 2011.
http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_
BGBl&jumpTo=bgbl111s2983.pdf. Accessed 5 Oct 2017.
34 Gemeinsamer Bundesausschuss (Federal Joint Committee).
Erprobungsregelung nach § 137e SGB V. 2017. https://www.g-ba.de/
institution/themenschwerpunkte/erprobungsregelung/. Accessed
5 Oct 2017.
35 Hess R, Deisler H, Siebig J. Stellungnahme der unparteiischen
Mitglieder des Gemeinsamen Bundesausschusses zum
Referentenentwurf eines Gesetzes zur Verbesserung der
Versorgungsstrukturen in der gesetzlichen Krankenversicherung für
die Anhörung des Bundesministeriums für Gesundheit am 29. Juni
2011. https://www.g-ba.de/downloads/17-98-3047/2011-06-27_SN_G-
BA%20GKV%20VSG.pdf?. Accessed 16 Apr 2017.
36 Coalition Agreement. Deutschlands Zukunft gestalten, Koalitionsvertrag
zwischen CDU, CSU und SPD, 18. Legislaturperiode, Berlin; 2013.
https://www.cdu.de/sites/default/files/media/dokumente/koalitionsvertrag.pdf.
Accessed 5 Oct 2017.
37 Gemeinsamer Bundesausschuss (Federal Joint Committee). Neue Methoden
mit Medizinprodukten hoher Risikoklasse: Erste Bewertungsverfahren nach §
137h SGB V abgeschlossen. 2017. https://www.g-ba.de/institution/presse/
pressemitteilungen/678/. Accessed 23 May 2017.
38 Wolf K, Dettlof M, Egger B. Hochrisiko-Medizinprodukte in der GKV: Was ist
eine innovationsfreundliche Gesundheitspolitik? G&S Gesundheits- und
Sozialpolitik. 2017;71(3-4):75–83.
39 Perry S, Gardner E, Thamer MW. The status of health technology assessment
worldwide. Results of an international survey. Int J Technol Assess Health
Care. 1997;13(1):81–98.
Olberg et al. Health Research Policy and Systems  (2017) 15:89 Page 10 of 11
40 Oortwijn W, Broos P, Vondeling H, et al. Mapping of health technology
assessment in selected countries. Int J Technol Assess Health Care.
2013;29(4):424–34.
41 Oortwijn W, Mathijssen J, Banta D. The role of health technology
assessment on pharmaceutical reimbursement in selected middle-income
countries. Health Policy. 2010;95(2-3):74–84.
42 Fuchs S, Olberg B, Panteli D, Busse R. Health technology assessment of
medical devices in Europe: processes, practices, and methods. Int J Technol
Assess Health Care. 2016;32(4):246–55.
43 Ettelt S. Evidence Advisory System Briefing Notes: Germany. Working
Paper. 2016. London School of Hygiene and Tropical Medicine.
http://researchonline.lshtm.ac.uk/3229543/1/EAS%20Briefing%20Note%205%20-
%20Germany.pdf. Accessed 10 Aug 2017.
44 Garrido MV, Kristensen FB, Nielsen CP, Busse R. Health Technology
Assessment and Health Policy-Making in Europe: Current Status, Challenges
and Potential. Copenhagen: World Health Organization on behalf of the
European Observatory on Health Systems and Policies; 2008.
45 Zens Y, Fujita-Rohwerder N, Windeler J. Nutzenbewertung von
Medizinprodukten. Bundesgesundheitsbl. 2015;58(3):240–7.
46 Institute for Quality and Efficiency in Health Care. New Study Again Shows:
More Strokes with Intracranial Stents. 2015. https://www.iqwig.de/en/press/
press-releases/press-releases/new-study-again-shows-more-strokes-with-
intracranial-stents.6729.html. Accessed 23 Apr 2017.
47 Löblová O. Three worlds of health technology assessment: explaining
patterns of diffusion of HTA agencies in Europe. Health Econ Policy Law.
2016;11(3):253–73.
48 Europe MT. The European Medical Technology industry. 2017. http://www.
medtecheurope.org/sites/default/files/resource_items/files/MEDTECH_
FactFigures_ONLINE3.pdf. Accessed 5 Oct 2017.
49 Gemeinsamer Bundesausschuss (Federal Joint Committee). Beschlüsse zu
"Erprobung". 2017. https://www.g-ba.de/informationen/beschluesse/zum-
aufgabenbereich/57/. Accessed 6 May 2017.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Olberg et al. Health Research Policy and Systems  (2017) 15:89 Page 11 of 11
